March 16, 2017
US Bioservices is now dispensing Novartis’ KISQALI
The U.S Food and Drug Administration recently approved Novartis’ KISQALI (ribociclib) for the treatment of postmenopausal women with HR+/HER2- advanced or metastatic breast cancer.
We use cookies and tracking technologies to offer you a better browsing experience, analyze site traffic, and improve the website. By clicking “Accept Cookies”, you expressly agree to our use of cookies and tracking technologies in accordance with our Cookie Policy. If you wish to prevent your data from being used by Google Analytics you can opt-out below.
Coronavirus (COVID-19) Update
AmerisourceBergen and our global businesses are highly engaged during the ongoing spread of the novel COVID-19 “Coronavirus."